Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib access study after ENACT in Hungarian adults with imatinib-resistant or imatinib-intolerant CML
2008-004467-19Phase 4Terminated
- Sponsor
- Novartis
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Continued access to nilotinib. Started Jul 2008; status: terminated.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2008-004467-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004467-19.